Patient and Provider Factors Associated With Initiating Sodium-Glucose Cotransporter-2 Inhibitors (SGTL2is) Following FDA Approval for Heart Failure With Preserved and Mildly Reduced Ejection Fraction-Reference-Cited by-同舟云学术

Patient and Provider Factors Associated With Initiating Sodium-Glucose Cotransporter-2 Inhibitors (SGTL2is) Following FDA Approval for Heart Failure With Preserved and Mildly Reduced Ejection Fraction

Published:2024-04 Issue:4 Volume:30 Page:630-632
ISSN:1071-9164
Container-title:Journal of Cardiac Failure
language:en
Short-container-title:Journal of Cardiac Failure

Author:

Martyn Trejeeve^ORCID,Saef Joshua,Bansal Agam,Martinez Kathryn A.,Block-Beach Hunter,Hohman Jessica,Kapadia Samir R.,Desai Milind Y.,Estep Jerry D.,Albert Nancy M.,Starling Randall C.,Tang W.H. Wilson

Publisher

Elsevier BV

Reference6 articles.

1. Heart failure drug treatment-inertia, titration, and discontinuation: a multinational observational study (EVOLUTION HF);Savarese;JACC Heart Fail,2023

2. Empagliflozin in heart failure with a preserved ejection fraction;Anker;N Engl J Med,2021

3. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction;Solomon;N Engl J Med,2022

4. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines;Heidenreich;Circulation,2022

5. The utilization and impact of cardiovascular specialists on guideline-directed medical scores: an analysis of a diverse, multi-state, electronic health record-based registry;Martyn;Eur J Heart Fail,2023

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In Reply: When should we consider SGLT-2 inhibitors in patients with acute decompensated heart failure?;Cleveland Clinic Journal of Medicine;2024-04